4 documents found, page 1 of 1
The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Co...
van Leth, F; Brinkmann, F; Cirillo, DM; Dheda, K; Duarte, R; Guglielmetti, L; Kuksa, L; Lange, C; Mitnick, C; Skrahina, A; Zaman, K; Bothamley, Gn/a
Management of patients with multidrug-resistant tuberculosis
Lange, C; Aarnoutse, RE; Alffenaar, JWC; Bothamley, G; Brinkmann, F; Costa, J; Chesov, D; van Crevel, R; Dedicoat, M; Dominguez, J; Duarte, RThe emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today. The World Health Organization reports that MDR-TB outcomes are poor despite staggeringly high management costs. Moreover, t...
Treatment outcomes of MDR-TB and HIV co-infection in Europe
Magis-Escura, C; Günther, G; Lange, C; Alexandru, S; Altet, N; Avsar, K; Bang, D; Barbuta, R; Bothamley, G; Ciobanu, A; Crudu, V; Davilovits, M
Beyond multidrug-resistant tuberculosis in Europe: a TBNET study
Günther, G; van Leth, F; Altet, N; Dedicoat, M; Duarte, R; Gualano, G; Kunst, H; Muylle, I; Spinu, V; Tiberi, S; Viiklepp, P; Lange, CThe emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone an...